BOZ, C. Et Al. 2023. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis. Neurological Sciences , vol.44, no.6 , 2121-2129.

BOZ, C., ÖZAKBAŞ, S., Terzi, M., KARABUDAK, R., Sevim, S., Turkoglu, R., ... Soysal, A.(2023). The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis. Neurological Sciences , vol.44, no.6, 2121-2129.

BOZ, CAVİT Et Al. "The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis," Neurological Sciences , vol.44, no.6, 2121-2129, 2023

BOZ, CAVİT Et Al. "The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis." Neurological Sciences , vol.44, no.6, pp.2121-2129, 2023

BOZ, C. Et Al. (2023) . "The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis." Neurological Sciences , vol.44, no.6, pp.2121-2129.

@article{article, author={CAVİT BOZ Et Al. }, title={The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis}, journal={Neurological Sciences}, year=2023, pages={2121-2129} }